BioMedNewsBreaks Archive - Page 77 of 174

WednesdayJul 20, 2022 2:18 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. “I had a unique,…

MondayJul 18, 2022 10:42 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its appointment of Michael Woudenberg as chief operating officer of the company, overseeing all day-to-day operations. Woudenberg previously served as senior vice president of chemistry, manufacturing and controls. For the past several years, he has been an integral part of InMed’s executive team, supporting multiple functions within the organization. Prior to joining InMed, Woudenberg had over 20 years of successful drug development, process engineering, GMP manufacturing and general management experience at all levels of various companies. “I would like to congratulate Mike…

ThursdayJul 14, 2022 1:59 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are…

ThursdayJul 14, 2022 11:20 am

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., will be featured in a new interview aired by RedChip Companies on The RedChip Money Report(R) on Bloomberg TV at 7 p.m. Eastern Time this Saturday, July 16. Bloomberg TV is available in an estimated 73 million homes across the U.S. In the exclusive interview, Odyssey Health’s spokesperson and Pro Football Hall of Fame quarterback Brett Favre discusses the major concussion he sustained in the final play of his professional career. Favre will share why he is proudly working to reduce and prevent concussions, the potential of Odyssey’s concussion treatment, and…

WednesdayJul 13, 2022 4:09 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs. “This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14…

WednesdayJul 13, 2022 2:57 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest episode of InvestorBrandNetwork’s Stock2Me podcast. Hosted by Stuart Smith, the podcast talks with soccer play Abby Wambach, an Olympic gold medalist and member of ODYY’s sports advisory board. During the interview, Wambach discusses her soccer career and why she was drawn to Odyssey, a medical technology company that is developing a drug/device combination intended to treat concussion. Wambach and other members of the sports advisory board support the company’s efforts to enhance public awareness of traumatic brain…

WednesdayJul 13, 2022 2:31 pm

BioMedNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that is wholly owned subsidiary, Lucid Psycheceuticals Inc., filed a provisional patent application on novel formulations of palmitoylethanolamide (“PEA”). According to the update, the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma. The company is diligently pursuing the clinical development of FSD201 for various indications. FSD Pharma recently announced the submission of an Investigational New Drug…

TuesdayJul 12, 2022 4:45 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity,” said Eric Weisblum, CEO of Silo Pharma. “In our previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and four hours was an optimal time point…

TuesdayJul 12, 2022 3:23 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said…

TuesdayJul 12, 2022 3:08 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human subjects. Concussions represent an “unmet” medical need and affect millions worldwide, while a single concussion can significantly increase the risk of Alzheimer’s and other neuropsychiatric disorders. “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

BioMedNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search